BRPI0814111A2 - Anticorpo monoclonal citotóxico anticâncer - Google Patents

Anticorpo monoclonal citotóxico anticâncer

Info

Publication number
BRPI0814111A2
BRPI0814111A2 BRPI0814111-8A2A BRPI0814111A BRPI0814111A2 BR PI0814111 A2 BRPI0814111 A2 BR PI0814111A2 BR PI0814111 A BRPI0814111 A BR PI0814111A BR PI0814111 A2 BRPI0814111 A2 BR PI0814111A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
cytotoxic monoclonal
cytotoxic
antibody
monoclonal
Prior art date
Application number
BRPI0814111-8A2A
Other languages
English (en)
Inventor
David S F Young
Helen P Findlay
Susan E Hahn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0814111A2 publication Critical patent/BRPI0814111A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023Lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814111-8A2A 2007-07-16 2008-07-14 Anticorpo monoclonal citotóxico anticâncer BRPI0814111A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94994207P 2007-07-16 2007-07-16
PCT/CA2008/001289 WO2009009882A1 (en) 2007-07-16 2008-07-14 An anti-cancer cytotoxic monoclonal antibody

Publications (1)

Publication Number Publication Date
BRPI0814111A2 true BRPI0814111A2 (pt) 2015-02-03

Family

ID=40259250

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814111-8A2A BRPI0814111A2 (pt) 2007-07-16 2008-07-14 Anticorpo monoclonal citotóxico anticâncer

Country Status (9)

Country Link
US (1) US20090022661A1 (pt)
EP (1) EP2178919A1 (pt)
KR (1) KR20100028642A (pt)
CN (1) CN101743255A (pt)
AU (1) AU2008278228A1 (pt)
BR (1) BRPI0814111A2 (pt)
CA (1) CA2692823A1 (pt)
TW (1) TW200920400A (pt)
WO (1) WO2009009882A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
CN102939934B (zh) * 2012-11-08 2017-01-18 同济大学 整体可视化人肺腺癌h1650裸鼠模型及其建立与应用
EP3029175A1 (en) 2014-12-05 2016-06-08 Basf Se Process for the production of porous thin films
WO2017093265A1 (en) 2015-11-30 2017-06-08 Basf Se Process for the generation of metallic films
EP3384063B1 (en) 2015-12-02 2019-09-18 Basf Se Process for the generation of thin inorganic films
WO2017129440A1 (en) 2016-01-27 2017-08-03 Basf Se Process for the generation of thin inorganic films
WO2017178400A1 (en) 2016-04-15 2017-10-19 Basf Se Process for the generation of thin inorganic films
EP3484901B1 (en) 2016-07-18 2022-06-15 Basf Se Hapto-3-pentadienyl cobalt or nickel precursors and their use in thin film deposition processes
CN109641927B (zh) 2016-08-31 2023-01-10 巴斯夫欧洲公司 用于生产薄无机膜的方法
EP3526363A1 (en) 2016-10-13 2019-08-21 Basf Se Process for the generation of metal-containing films
CN109890997A (zh) 2016-10-25 2019-06-14 巴斯夫欧洲公司 产生薄含硅膜的方法
WO2018108628A1 (en) 2016-12-13 2018-06-21 Basf Se Process for the generation of thin silicon-containing films
EP3728688B1 (en) 2017-12-20 2021-11-10 Basf Se Process for the generation of metal-containing films
WO2019201692A1 (en) 2018-04-17 2019-10-24 Basf Se Aluminum precursor and process for the generation of metal-containing films
WO2019206746A1 (en) 2018-04-23 2019-10-31 Basf Se Process for the generation of metal-containing films

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471206A1 (en) * 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
US20090022661A1 (en) 2009-01-22
CN101743255A (zh) 2010-06-16
KR20100028642A (ko) 2010-03-12
CA2692823A1 (en) 2009-01-22
EP2178919A1 (en) 2010-04-28
WO2009009882A1 (en) 2009-01-22
AU2008278228A1 (en) 2009-01-22
TW200920400A (en) 2009-05-16

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
NO344963B1 (no) Humanisert antistoff
SMT201700083B (it) Anticorpi monoclonali
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2274012T3 (da) Cytotoksisk immunoglobulin
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
DK2131860T3 (da) Anti-sclerostin-antistoffer
ZA201000049B (en) Monoclonal antibeta amyloid antibody
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0820819A2 (pt) Formulação de anticorpos
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
SG10201601279SA (en) Monoclonal Antibody STRO-4
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2331579A4 (en) MONOCLONAL ANTIBODIES
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: G01N 33/574 (2006.01), A61K 47/68 (2017.01), A61K